Author

Iris Dotan

EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL
EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL

What I regretted most in IBD treatment
What I regretted most in IBD treatment

Iris Dotan

Tandem Talk - Drug therapy: The easy and the challenging patient
Tandem Talk - Drug therapy: The easy and the challenging patient

Iris Dotan  et al.

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS
ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Iris Dotan

SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Insights in pouch pathophysiology
Insights in pouch pathophysiology

Iris Dotan

EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL
EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL

Iris Dotan  et al.

CANNABIS INDUCES SIGNIFICANT CLINICAL AND QOL IMPROVEMENT IN CHRONIC POUCHITIS
CANNABIS INDUCES SIGNIFICANT CLINICAL AND QOL IMPROVEMENT IN CHRONIC POUCHITIS

Iris Dotan  et al.

THE RISK FOR ADVANCED NEOPLASIA AFTER POLYPECTOMY OF UP TO TWO DIMINUTIVE POLYPS WITH LOW GRADE DYSPLASIA VS. NORMAL COLONOSCOPY
THE RISK FOR ADVANCED NEOPLASIA AFTER POLYPECTOMY OF UP TO TWO DIMINUTIVE POLYPS WITH LOW GRADE DYSPLASIA VS. NORMAL COLONOSCOPY

Iris Dotan  et al.

RATE OF INAPPROPRIATE PROTON PUMP INHIBITORS PRESCRIPTION AT DISCHARGE FROM INTERNAL MEDICINE DEPARTMENTS ACCORDING TO A DEVELOPED ALGORITHM
RATE OF INAPPROPRIATE PROTON PUMP INHIBITORS PRESCRIPTION AT DISCHARGE FROM INTERNAL MEDICINE DEPARTMENTS ACCORDING TO A DEVELOPED ALGORITHM

Iris Dotan  et al.

MACHINE LEARNING AS A DECISION-SUPPORT TOOL FOR SELECTING PATIENTS WITH CROHN'S DISEASE FOR ABDOMINOPELVIC CT IN THE EMERGENCY DEPARTMENT
MACHINE LEARNING AS A DECISION-SUPPORT TOOL FOR SELECTING PATIENTS WITH CROHN'S DISEASE FOR ABDOMINOPELVIC CT IN THE EMERGENCY DEPARTMENT

Iris Dotan  et al.

PERIANAL CROHN'S DISEASE IN CHILDREN IS ASSOCIATED WITH MORE HOSPITALIZATIONS AND SURGERIES DESPITE HIGHER UTILIZATION OF IMMUNOMODULATORS AND BIOLOGICS: A REPORT FROM THE EPIIIRN COHORT
PERIANAL CROHN'S DISEASE IN CHILDREN IS ASSOCIATED WITH MORE HOSPITALIZATIONS AND SURGERIES DESPITE HIGHER UTILIZATION OF IMMUNOMODULATORS AND BIOLOGICS: A REPORT FROM THE EPIIIRN COHORT

Iris Dotan  et al.

ROLE OF MAFB TRANSCRIPTION FACTOR IN HUMAN INTESTINAL METAPLASIA AND GASTRIC CANCER BIOPSIES
ROLE OF MAFB TRANSCRIPTION FACTOR IN HUMAN INTESTINAL METAPLASIA AND GASTRIC CANCER BIOPSIES

Iris Dotan  et al.

PATIENTS WITH NEWLY DIAGNOSED FISTULIZING PERIANAL CROHN'S DISEASE HAVE DISTINCT MICROBIAL SIGNATURE
PATIENTS WITH NEWLY DIAGNOSED FISTULIZING PERIANAL CROHN'S DISEASE HAVE DISTINCT MICROBIAL SIGNATURE

Iris Dotan  et al.

PERI-PARTUM INFECTIONS AMONG WOMEN WITH INFLAMMATORY BOWEL DISEASE
PERI-PARTUM INFECTIONS AMONG WOMEN WITH INFLAMMATORY BOWEL DISEASE

Iris Dotan  et al.

RESPONSIVENESS OF FECAL CALPROTECTIN AND QUALITY OF LIFE QUESTIONNAIRES TO CHANGE IN POUCH DISEASE ACTIVITY. RESULTS FROM A PROSPECTIVE TRIAL
RESPONSIVENESS OF FECAL CALPROTECTIN AND QUALITY OF LIFE QUESTIONNAIRES TO CHANGE IN POUCH DISEASE ACTIVITY. RESULTS FROM A PROSPECTIVE TRIAL

Iris Dotan  et al.

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Iris Dotan  et al.

INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE
INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE

Iris Dotan  et al.

A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE
A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE

Iris Dotan  et al.

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Iris Dotan  et al.

Item 1 - 20 / 39
1
2